𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Cisplatin. A phase II evaluation in previously untreated patients with soft tissue sarcomas

✍ Scribed by Peter P. Sordillo; Gordon B. Magill; Joseph Brenner; Edgar W. Cheng; Michael Dosik; Alan Yagoda

Publisher
John Wiley and Sons
Year
1987
Tongue
English
Weight
232 KB
Volume
59
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Phase II trial of cisplatin (CPDD) in pr
Phase II trial of cisplatin (CPDD) in previously treated patients with advanced soft tissue sarcoma
✍ Joseph Brenner; Gordon B. Magill; Peter P. Sordillo; Edgar W. Cheng; Allan Yagod πŸ“‚ Article πŸ“… 1982 πŸ› John Wiley and Sons 🌐 English βš– 249 KB πŸ‘ 1 views

Thirty-six previously treated adult patients with advanced soft tissue sarcomas received CPDD 120 mg/m2 with mannitol diuresis. There were only two (6%) partial responses and five (15%) minor responses in 34 evaluable patients. Toxicity included nausea and vomiting, myelosuppression, mild ototoxicit

Clinical outcome of patients with previo
Clinical outcome of patients with previously untreated soft tissue sarcomas in relation to tumor grade, DNA ploidy and karyotype
✍ Boudewijn E.C. Plaat; Friso L.H. Muntinghe; Willemina M. Molenaar; Harald J. Hoe πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 French βš– 94 KB πŸ‘ 1 views

The most important prognostic factor in soft tissue sarcomas (STS) is tumor grade. Since most grading methods are subject to the interpretation of the individual pathologist, there is a need for objective criteria such as DNA ploidy and karyotype, which are of prognostic value in several types of ma

The efficacy of a combination of etoposi
The efficacy of a combination of etoposide, ifosfamide, and cisplatin in the treatment of patients with soft tissue sarcoma
✍ Zs. PΓ‘pai; Gy. Bodoky; J. SzΓ‘ntΓ³; I. Poller; P. RahΓ³ty; S. Eckhardt; I. LΓ‘ng; M. πŸ“‚ Article πŸ“… 2000 πŸ› John Wiley and Sons 🌐 English βš– 62 KB πŸ‘ 1 views

## BACKGROUND. Successful chemotherapy for patients with soft tissue sarcoma (STS) has been limited by a lack of active drugs. The most effective single agents are doxorubicin, dacarbazine, and, more recently, ifosfamide. Previously the most widely used combination has been CYVADIC (cyclophosphami